AUTOLUS THERAPEUTICS PLC - AMERICAN DEPOSITARY SHA

Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

11 Oct 2023 07:07:12 By Nasdaq GlobeNewswire

Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

11 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress

03 Aug 2023 06:00:01 By Nasdaq GlobeNewswire

Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer

19 Jul 2023 06:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023

18 Jul 2023 06:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic Leukemia

06 Jul 2023 06:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics announces publication in Cancer Immunology Research

27 Jun 2023 06:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics strengthens its Board with the appointment of Dr. Robert Iannone as a Non-Executive Director

20 Jun 2023 06:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma

16 Jun 2023 06:00:00 By Nasdaq GlobeNewswire

Autolus to hold Annual General Meeting (AGM) of Shareholders on Friday, June 30, 2023

06 Jun 2023 06:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO

02 Jun 2023 06:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics to hold Analyst call to highlight data at ASCO from the Pivotal Phase 2 FELIX study of obe-cel data in adult r/r B-ALL

22 May 2023 06:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at EHA

12 May 2023 06:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics Reports First Quarter 2023 Financial Results and Operational Progress

04 May 2023 06:00:02 By Nasdaq GlobeNewswire

Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at ASCO

27 Apr 2023 06:01:00 By Nasdaq GlobeNewswire

Autolus Therapeutics Selects Cardinal Health as U.S. Commercial Distribution Partner

27 Apr 2023 06:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics Announces Publication in Molecular Therapy Nucleic Acids

26 Apr 2023 15:01:00 By Nasdaq GlobeNewswire

Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia in an Oral Presentation at the EBMT 49th Annual Meeting

26 Apr 2023 06:06:00 By Nasdaq GlobeNewswire

Autolus Therapeutics to Host Virtual Capital Markets Day

25 Apr 2023 06:00:01 By Nasdaq GlobeNewswire

Autolus Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023

20 Apr 2023 06:00:00 By Nasdaq GlobeNewswire